T. Colberg

A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial

Sebastiano Mercadante, Lukas Radbruch, Andrew Davies et al. · Current Medical Research and Opinion · 2009 · 164 citations

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period

Hans G. Kress, Anna Orońska, Zbigniew Kaczmarek et al. · Clinical Therapeutics · 2009 · 141 citations

Medicine, Pharmacology, Pharmacotherapy +17

Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9‐GP), a glycoPEGylated recombinant factor IX

Peter W. Collins, Karin Knobe, Andreas Groth et al. · Journal of Thrombosis and Haemostasis · 2012 · 64 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +10

Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4)

Guy Young, Peter W. Collins, T. Colberg et al. · Thrombosis Research · 2016 · 59 citations · Full text

Medicine, Hematology, Pharmacology +5

Low‐factor consumption for major surgery in haemophilia B with long‐acting recombinant glyco<scp>PEG</scp>ylated factor <scp>IX</scp>

Miguel A. Escobar, Ramin Tehranchi, Faraizah Abdul Karim et al. · Haemophilia · 2016 · 34 citations

Medicine, Perioperative Medicine, Surgery +16